MindMaze Therapeutics Holding SA (RLFTF)

Overview

MindMaze Therapeutics Holding SA is a Switzerland-based life sciences company that focuses on precision neurology and brain health through an innovative AI-enabled neurotechnology platform. The company was formed through the merger of NeuroX Group and Relief Therapeutics, creating a unique integration of biopharmaceutical development aimed at addressing rare and specialty diseases alongside digital therapeutics, motion analytics, and proprietary devices. By providing solutions for motor and cognitive rehabilitation, MindMaze Therapeutics is committed to enhancing quality of life for patients. The company has successfully treated over 35,000 patients, achieved multiple regulatory approvals, and is in possession of a distinct US CAT-3 reimbursement code. This positions MindMaze at the forefront of bridging biopharma and digital health, ensuring that care is available across a continuum from acute medical settings to home environments. Additionally, the firm actively seeks partnerships with pharmaceutical companies and service providers to tackle the unmet needs in the field of neurology.

Products and Services

• MindPod:

  An immersive platform designed for brain recovery, MindPod leverages virtual reality and interactive experiences to facilitate cognitive rehabilitation and sensory integration, promoting faster recovery and enhanced patient engagement.

• MindMotion GO:

  This neurorehabilitation system is suitable for both clinical use and home settings. It offers personalized therapy programs that adapt to individual patient progress, thereby maximizing rehabilitation outcomes through engaging and interactive motional exercises.

• Izar:

  Izar is a specialized hand training peripheral aimed at patients suffering from conditions such as stroke and Parkinson’s disease. This device helps to improve hand function through targeted exercises, enhancing fine motor skills and promoting independence.

• Physilog:

  Physilog is a cutting-edge tool for conducting 3D motion assessments and capturing digital biomarkers. This technology aids healthcare professionals in monitoring patient progress and tailoring rehabilitation strategies effectively.

• Physiomimic:

  A proprietary delivery technology employed to advance drug candidates targeting rare metabolic and dermatological diseases, Physiomimic enhances the efficacy of treatments by mimicking natural biological processes.

• TEHCLO:

  TEHCLO is another proprietary delivery technology that plays a crucial role in the development of innovative therapies. It aims to optimize drug delivery methods for better absorption and therapeutic benefits in challenging medical scenarios.